In conclusion, our study demonstrated the ability of MAP3K1 to modulate the tumor microenvironment via regulation of tumor antigen presentation and highlighted the clinical potential of the postbiotic Tyra to enhance immunotherapy efficacy in HR+/HER2– breast cancer. The gene discussed is ERBB2; the disease is breast cancer.